July 27, 2023

Corporate Travel Management' financial update for FY23

By Roger Montgomery

With reporting season about to begin and confession season well-underway, analysts are keen to understand the extent to which any pullback in consumer activity has, for example, impacted business. Thus far, earnings momentum has tilted negatively.
July 26, 2023

Aura private credit: Letter to investors 21 July 2023

By Brett Craig

The Aura Private Credit strategies partner with best of breed non-bank lenders who provide Australian SMEs with specialised funding solutions. These lenders utilise alternative security forms which the banks may be unable to use due to prudential regulations that govern the banking system in Australia.
July 25, 2023

Why small caps could rally from here

By Roger Montgomery

Back on 12 October last year, with the S&P500 in the grip of a bear market, we published a blog titled “Why it might be time to be greedy once more”. It’s turned out to be a good call, as the index has since gained 21 per cent.
July 24, 2023

Why Polen Capital own retailer Five Below

By David Buckland

Our global investment partner, Polen Capital, seeks to invest in high-quality companies that have strong growth potential and competitive advantages. In this article, I explore a U. S. -based retail businesses owned by the Polen Capital Small and Mid Cap Fund – Five Below. Five Below is a discount chain that sells products that cost up to U. S.
July 17, 2023

Private Credit: a smart choice

By Roger Montgomery

  For many years I’ve advocated investment in equities. That won’t change. I believe owning quality growing businesses is the surest way to long-term wealth creation. A quick glance at the ‘rich lists’ of the wealthiest people in Australia, for example, reveals a list of business owners.
July 13, 2023

Exploring the growth prospects of Endava and Globant: pioneering companies in digital transformation and software development

By David Buckland

  In this week’s video insight David Buckland introduces two companies in the Polen Capital Small and Mid Cap Fund: Endava and Globant. Endava is a British software development and consulting firm experiencing steady revenue growth and global expansion. Globant is a global IT company focusing on AI and software development.
July 12, 2023

Telix Pharmaceuticals – strong momentum ahead

By David Buckland

Telix Pharmaceuticals Limited (ASX:TLX) is a Melbourne-headquartered $3. 9 billion company which recently entered the Montgomery and Australian Eagle portfolios and seems to have very exciting prospects. To backtrack, Telix’s targeted radiation imaging and therapy technologies have potential to transform the way clinicians can find and manage cancer to inform treatment decisions and deliver personalised therapy.
July 10, 2023

Farewell fiscal 2023, hello fiscal 2024

By David Buckland

The period from late 2021 into much of 2022 saw strong rising official cash rates and widespread worries about an upcoming recession, equities mostly surprised by delivering strong performance in the financial year of 2023. Investors demonstrated remarkable resilience and adaptability as they actively pursued opportunities in the market.
July 5, 2023

Home-grown Australian biomedical companies shine on the global stage

By David Buckland

  In this week’s video insight David Buckland discusses two Australian biomedical companies, Pro-Medicus (ASX:PME) and Telix Pharmaceuticals (ASX:TLX) which are gaining global recognition. Pro-Medicus specialises in imaging software and has experienced significant growth, while Telix focuses on cancer management technologies with promising market potential. Both companies are poised for further success and expansion.

Funds

View all funds